Parliament Question: Targets of biotech Industry

1. At a Glance

• Parliament Question (Lok Sabha, 02 April 2026) in Ministry of Science & Technology on the targets and trajectory of India's biotech industry, anchored in the National Biotech Development Strategy 2021 and the BioE3 Policy 2024 [1][2].
• India's bioeconomy crossed USD 150 bn in 2023 (two years ahead of schedule) and reached USD 165.7 bn by end-2024, on a glide-path to USD 300 bn by 2030 [1][3].
• Relevant for GS-III (Science & Tech, Economy) — links industrial policy, biotech R&D, biomanufacturing and the start-up ecosystem [2].

2. Why in the News

• PIB release dated 02 April 2026 by Ministry of Science & Technology answering a Parliament Question on biotech industry targets [1].
• Follow-up to the BioE3 Policy approved by the Union Cabinet on 24 August 2024 [4].
• Bioeconomy hit USD 195.3 bn in 2025 (18% YoY growth), tracking the USD 300 bn-by-2030 target [5].

3. Background & Evolution

• Department of Biotechnology (DBT) set up in 1986 under Ministry of Science & Technology [2].
• BIRAC — Public Sector Enterprise of DBT — established to catalyse industry-academia translational research [1].
• National Biotech Development Strategy 2021 prioritised innovation and manufacturing excellence [1].
• BioE3 Policy (2024) — Biotechnology for Economy, Environment and Employment — for high-performance biomanufacturing [4].
• Bio-RIDE Scheme (umbrella scheme) merges Biotech R&D, Industrial & Entrepreneurship Development, and BioE3 [5].

4. Core Static Facts

• Nodal Ministry: Ministry of Science & Technology → Department of Biotechnology (DBT) [1].
• Implementing PSU: Biotechnology Industry Research Assistance Council (BIRAC) [1].
• Anchor Policy: BioE3 Policy, approved by Cabinet 24 Aug 2024 [4].
• Bioeconomy size: USD 10 bn (2014) → USD 151 bn (2023) → USD 165.7 bn (2024) → USD 195.3 bn (2025) [3][5].
• CAGR: 17.9% over last 4 years; 4.25% share of GDP [3].
• 2030 Target: USD 300 bn bioeconomy [3].
• Sectoral split (2030 projections): BioMedical USD 128 bn; BioIndustrial USD 121 bn; BioServices USD 42.4 bn; BioAgriculture USD 39.3 bn [3].
• Biotech start-ups: 5,365 (2021) → ~13,000 (2025), +142% [3].
• BIRAC incubators: 94 centres under BioNEST + E-YUVA, focused on healthcare [5].
• India's first Biofoundry Network: 15 bio-enabler facilities under DBT-BIRAC [5].

5. Multi-Dimensional Analysis

Economic

• Bioeconomy contributes 4.25% of GDP, with 17.9% CAGR outpacing overall GDP growth [3].
• BioE3 targets job-generation in Tier-II/III cities using local biomass — addresses regional inequity [3].

Scientific / Technological

• BioE3 pillars: bio-foundry clusters, bio-AI hubs, advanced biomanufacturing facilities [4].
• Focus areas: bio-based chemicals, smart proteins, precision biotherapeutics, climate-resilient agri, marine & space biotech [4].

Environmental

• Push for sustainable biomanufacturing to substitute petrochemical pathways → aligned with net-zero & circular bioeconomy [4].

Administrative / Governance

• Bio-RIDE consolidates fragmented DBT schemes; TDB and BIRAC designated as Second-Level Fund Managers under RDI scheme (calls launched Feb 2026) [5].

Strategic

• Positioning India as a global biopharma & biomanufacturing hub, reducing import-dependence in APIs and bio-enzymes [4].

6. Recent Developments (12-18 months)

• 24 Aug 2024: Cabinet approves BioE3 Policy [4].
• End-2024: Bioeconomy hits USD 165.7 bn [1].
• 2025: Indian Bioeconomy Report 2025 published by BIRAC [1]; sector reaches USD 195.3 bn [5].
• Feb 2026: TDB and BIRAC launch RDI-scheme proposal calls as SLFMs [5].
• 02 Apr 2026: Parliament Question on biotech industry targets answered [1].

7. Prelims Hooks

• Nodal Department: DBT under Ministry of Science & Technology — not MoHFW [1].
• BIRAC is a Section 8 / Not-for-profit PSU of DBT, not an autonomous statutory body [1].
• BioE3 stands for Biotechnology for Economy, Environment and Employment [4].
• BioE3 Policy approved on 24 August 2024 [4].
• India's bioeconomy: USD 165.7 bn at end-2024, USD 195.3 bn in 2025 [1][5].
• Target: USD 300 bn by 2030 [3].
• CAGR ~17.9%; contributes 4.25% of GDP [3].
• Biotech start-ups: ~13,000 in 2025 (from 5,365 in 2021) [3].
• BioNEST + E-YUVA: 94 BIRAC incubation centres [5].
• Biofoundry Network launched with 15 facilities by DBT-BIRAC [5].
• Bio-RIDE = umbrella scheme covering BioE3 + R&D + Industrial/Entrepreneurship verticals [5].
• National Biotech Development Strategy released in 2021 [1].

8. Mains Relevance

• GS-III — Science & Technology (Biotechnology); Indian Economy (Growth & Industrial Policy); Achievements of Indians in S&T.
• Possible stems: 1. "The BioE3 Policy is India's bridge between climate action and industrial competitiveness." Discuss. 2. Evaluate the role of BIRAC in catalysing India's biotech start-up ecosystem. 3. Examine the feasibility of India's USD 300 billion bioeconomy target by 2030 and the institutional gaps in achieving it.

9. Related Topics to Study Next

• National Biopharma Mission — DBT-BIRAC flagship preceding BioE3.
• Bio-RIDE Scheme — umbrella architecture for biotech funding.
• Anusandhan National Research Foundation (ANRF) — apex R&D body.
• RDI Scheme & Deep-Tech Fund of Funds — adjacent innovation finance vehicles.
• GM crops & GEAC — regulatory side of biotech.
• PLI for Pharma & Bulk Drugs — manufacturing-policy linkage.
• National Quantum Mission / Semicon India — comparative deep-tech missions.
• Cartagena Protocol on Biosafety — international biotech governance.

10. Common Errors / Trap Areas

• BIRAC ≠ statutory body — it is a Section 8 PSU under DBT, not created by Act of Parliament.
• BioE3 ≠ BioRRAP / Bio-RIDE — BioE3 is a policy (2024); Bio-RIDE is the umbrella scheme.
• USD 300 bn target year is 2030, not 2025 or 2047.
• DBT is under Min. of Science & Technology, not Ministry of Health or Ministry of Agriculture.
• Bioeconomy figure for 2024 is USD 165.7 bn — easily confused with the 2023 figure of USD 151 bn.